India’s pharma sector is projected to touch around USD 65 billion by 2024, and nearly USD 130 billion by 2030. It could expand to about USD 450 billion by 2047. Curis Lifesciences Limited, a company working in this sector, is gearing up for the IPO.
The IPO is managed by Finaax Capital Advisor. Moreover, MUFG Intime is registering the issue. Check the Curis Lifesciences allotment status now.
To know more about the IPO, check out the Curis Lifesciences Limited DRHP and RHP.
Note: 50% shares will be unlocked 30 days after allotment, while the rest will be free from lock-in restrictions after 90 days.
Here is the full Curis Lifesciences IPO review.
Let's see the risks and strengths you should know about this Curis Lifesciences:
Experienced team: The company is guided by promoters who’ve spent over a decade in the pharma world. With their medical knowledge, they know the industry inside out.
Big product variety: From tablets to syrups, the company makes a wide range of medicines.
Quality you can count on: Every product is made with care and attention. The company always aims to deliver the same trusted quality.
Customers come first: The business runs on a simple idea and understands what customers want and delivers it right.
Risks
All operations in one place: The company runs its main factory in Sanand, Ahmedabad. If anything unexpected happens, like a policy change, a natural disaster, or a local issue, it could slow down work or affect earnings.
Heavy rules to follow: Since it’s in the pharma business, the company has to get several approvals from health and government authorities.
Changing raw material costs: The prices of key ingredients keep going up and down. If costs rise too much, it could reduce profits and make it harder to manage expenses.
Possible loan payment delays: If the company delays any loan instalments, it might have to pay penalties or face extra pressure from banks.
As of November 3, 2025, the Curis Lifesciences IPO GMP hasn’t been updated yet. You can still check the IPO's live GMP and the subscription status numbers. Also, it’s a good idea to run through the Curis Lifesciences DRHP before you hit Apply Now.
1. How is the Curis Lifesciences IPO review?
Curis Lifesciences Limited is a pharmaceutical company. However, you can check the IPO date, size, and Curis Lifesciences Ltd turnover in its DRHP. For the latest details, you can also look for the GMP updates.
2. What is the Curis Lifesciences Ltd IPO date?
The IPO open date is November 7, 2025, and the close date is November 11, 2025, as of November 3, 2025. Live subscription details can be monitored through FinnPick.
3. What is the Curis Lifesciences IPO price?
The Curis Lifesciences IPO price is ₹120 to ₹128 as of November 3, 2025. Also, don't forget to check the Curis Lifesciences RHP.
4. Should I use a demat account to bid for the Curis Lifesciences Limited IPO?
Yes, a demat account is required to bid for the Curis Lifesciences Limited IPO. Click here to get the ultimate list of the top demat account providers.
